<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>238-FOLATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FOLATES" code="V03-" /></DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>238-FOLATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FOLATES" code="V03-" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
